What’s new in karyotyping? The move towards array comparative genomic hybridisation (CGH) by unknown
REVIEW
What’s new in karyotyping? The move towards array
comparative genomic hybridisation (CGH)
Thomy J. L. de Ravel & Koen Devriendt &
Jean-Pierre Fryns & Joris R. Vermeesch
Received: 8 January 2007 /Accepted: 27 February 2007 / Published online: 20 March 2007
# Springer-Verlag 2007
Abstract Molecular karyotyping by array comparative
genomic hybridisation (array CGH) has doubled the
detection rate of pathogenic chromosomal imbalances in
patients. This has been possible by increasing the resolution
level from the 5 Mb obtained using the conventional
karyotype to as low as 100 kb by array technology.
Moreover, the technology revealed that over 12% of the
human genome includes sub-microscopic benign copy
number variable regions. These new findings have impli-
cations in genetic counselling and patient management.
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Abbreviations
Array CGH array comparative genomic hybridisation
BAC bacterial artificial chromosome
Cy cyanide dye
dCTP deoxycytidine triphosphate
FISH fluorescence in situ hybridisation
kb kilobases
Mb megabases
MCA multiple congenital anomalies
MR mental retardation
PAC p1 artificial chromosome
SNP single nucleotide polymorphism
Introduction
Routine chromosome analysis, or karyotyping, has success-
fully been used for the last 50 years in investigating the
cause in patients with mental retardation, specific organ
malformations and dysmorphism, whether or not they are
part of a syndrome. This has also led to the discovery of
genes responsible for various conditions. Standard karyo-
typing is, however, constrained by the limits of resolution
possible by using a microscope. The advent of molecular
karyotyping, whereby sub-microscopic copy number
changes across the whole genome are evaluated in a single
analysis, has greatly increased the detection of pathogenic
chromosome imbalances. Whereas standard karyotyping
and fluorescence in situ hybridisation (FISH) studies
detected chromosome imbalances in 10% of patients with
mental retardation, molecular karyotyping has added an
additional 10% of detection. This is having a great impact
on the understanding of pathologies, the counselling of
families and patient management [25].
Background
The human chromosome number of 46 was discovered as
recently as 1956 [23], and aneuploidy in 1959 when
Lejeune et al. [8] reported trisomy 21 (OMIM 190685) to
be the common underlying cause in individuals with the
characteristic mental retardation syndrome, also known as
Down syndrome. The development of better culture and
slide preparations, and the introduction of banding tech-
niques in the 1970s, facilitated the identification of each
individual chromosome, and soon, chromosome aberrations
were reported in a number of patients with syndromes, as
well as in aborted and stillborn foetuses. The occurrence of
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non-pathogenic variations (polymorphisms) was also noted.
Present-day standard karyotyping, carried out on dividing
cells and using a 10,000× magnification, detects numerical
as well as structural chromosome aberrations, such as
deletions, duplications, inversions and translocations, as
long as they involve at least 5 to 10 million base pairs of
DNA (5–10 Mb resolution) (Fig. 1).
Further refinement in the form of fluorescence in situ
hybridisation (FISH) uses labelled DNA probes to detect the
presence, number and location of small (sub-microscopic)
regions of chromosomes, each probe hybridising to a spe-
cific already-known DNA sequence. This can confirm the
clinical suspicion of known microdeletion syndromes, such
as the velocardiofacial (VCFS, 22q11 deletion, OMIM
192430, Fig. 2), William’s (7q11.23 deletion, OMIM
194050) and Prader-Willi (15q11.2–13 deletion, OMIM
176270) syndromes. FISH also detects deletions in the gene-
rich subtelomeres which are involved in mental retardation
and a number of syndromes, such as the Wolf-Hirschhorn
(deletion 4p, OMIM 194190) and chromosome 1p36 deletion
(OMIM 607872) syndromes. Using 27 different fluorescent
DNA probes simultaneously, “whole chromosome painting”
shows re-arrangements at a 1 to 5 Mb resolution but not
deletions, duplications and inversions [21].
Tumour tissue was long-known to have chromosome re-
arrangements, especially deletions or duplications (amplifi-
cations). In order to detect these regions (and eventually
relate them to prognosis), differentially labelled patient
DNA and normal reference DNA were simultaneously
hybridised to normal metaphase spreads. Regions of loss
Fig. 1 Standard Giemsa-banded
karyotype of a female patient
Fig. 2 Fluorescence in situ
hybridisation (FISH) analysis
using probe 22q11 (red colour) to
demonstrate a normal individual
(a) and an individual with a
deletion of the chromosome
22q11 region (b). The green
fluorescent probe is a control
probe on chromosome 22
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(deletions) and gain (duplications) were seen as changes in
the intensities of the two fluorochromes along the chromo-
somes. This map of DNA sequence copy number as a
function of chromosome location was termed comparative
genomic hybridisation (CGH) [6]. As chromosomes are used
as the template, the resolution is still only 3–5Mb nowadays.
Solinas-Toldo et al. [20] and Pinkel et al. [12] developed
array CGH, whereby the hybridisation of the patient DNA
takes place on an array of mapped DNA clones instead of
metaphase chromosomes. Although chromosomes are no
longer visualised under a microscope, the term “molecular
karyotyping” is used for this group of techniques since, in
analogy to conventional karyotyping, the purpose is the
identification of chromosomal imbalances [27].
The array CGH technology
Genomic DNA of the patient is extracted from peripheral
blood lymphocytes, skin fibroblasts or other available tissue
and labelled with one fluorescent dye (usually Cy3-labelled
dCTPs). The labelled patient DNA, together with an equal
amount of control DNA labelled with another fluorescent
dye (usually Cy5-labelled dCTPs ), are co-hybridised to a
selected set of pre-spotted genomic fragments [26]. The
spot intensities are measured at 532 nm (Cy3) and 635 nm
(Cy5). If the amount of Cy3 and Cy5 fluorescent intensities
are equal in one spot, this region of the patient DNA is
interpreted as being normal/balanced; if a threshold of
increased ratio of Cy3 to Cy5 is detected, a duplication of
the patient DNA is suspected, and inversely if a deletion is
present (Fig. 3). In the last three years, studies with BAC/
PAC arrays having a 1-Mb resolution have been the most
frequently performed (Table 1). Thus, imbalances of 1 Mb
and more can be detected with this technique. Following
these initial studies, several technical platforms at increas-
ingly higher resolution have been developed. These include
the full tiling BAC arrays, cDNA arrays, oligonucleotide
and the SNP arrays, with theoretical resolutions of up to
6 kb. In addition to the information obtained using BAC
arrays, a special type of oligonucleotide array can
distinguish SNPs, allowing recognition of the parental
origin of each DNA copy and enabling the detection of
uniparental disomy (UPD); this is important in UPD
disorders and cancers. A number of targeted microarrays
(e.g. only for the analysis of subtelomeric and micro-
deletion syndrome regions) are also offered in various
centres (reviewed in [25]).
Deletion
DuplicationArray of DNA fragments

















Fig. 3 a The array comparative genomic hybridisation (CGH)
technique. b An example of the spotted plate. c Schematic
representation of the results of the DNA of a patient with a
chromosome 13 deletion co-hybridised against the DNA of a normal
control. The DNA clones of chromosomes 1 to 22 and the sex
chromosomes are aligned along the X axis (left to right), whilst the log
score of the fluorescent analysis obtained for each clone is given along
the Y axis. The deletion (seen in red on the spotted plate in a and b) is
represented by negative log scores whilst a duplication (green on
spotted plate in a and b) is seen as positive log scores. Thus, the
chromosome 13 deletion in this patient is represented by negative log
scores of the corresponding clones (shown within the red circle)
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Clinical applications of array CGH
Mental retardation and dysmorphism
Eight studies screening individuals with mental retarda-
tion, multiple dysmorphic features and normal traditional
karyotypes have demonstrated a high diagnostic yield in
MCA/MR patients (Table 1). In summary, at the 1-Mb
resolution, 20% to 25% of selected individuals have
deletions or duplications or a combination of both.
About half of these are conclusively causal for the
disorder. The few studies at 100-kb resolution have also
detected about 10% of pathogenic interstitial aberrations.
The chromosome imbalances occur throughout the
genome and are often single cases. In order to correlate
the aberrant genotypes with the phenotypes worldwide,
collaborative databases of results have been set up, e.g.
Decipher (http://www.sanger.ac.uk/PostGenomics/decipher/)
and Ecaruca (http://www.ECARUCA.net). Two new
microdeletion syndromes have, thus far, been delineated
using array CGH. An interstitial microdeletion at chromo-
some 9q22.3 is associated with a syndrome comprising
of macrocephaly, overgrowth, psychomotor retardation
and facial dysmorphism [13]. Similarly, a chromosome
17q21.31 microdeletion associated with a common inver-
sion polymorphism results in a new syndrome comprising
of moderate mental retardation, marked hypotonia, a long
facies, blepharophimosis, ptosis, pear-shaped nose with a
broad tip, long columella, large ears and a broad chin
[7, 19].
Translocations
Disruption of dosage-sensitive genes at the translocation
breakpoints has long been suspected in patients with mental
retardation and/or dysmorphic features. Using array CGH
and sequence analyses, both affected patients and normal
apparently balanced translocation carrier-parents were
shown to have not only insertions and duplications but
also disrupted genes at the site of the translocations. More
so, with the aid of array CGH, a significant proportion of
translocation patients were found to have complex chro-
mosome re-arrangements both in the chromosomes in-
volved in the translocation as well as in other chromosomes
[1, 5]. The non-translocation-related chromosome imbal-
ance is, in some cases, responsible for the phenotype.
Prenatal investigation
Array CGH can be carried out on the DNA of single cells,
of chorionic villus biopsies and of amniocytes. Due to the
complexity in interpreting a complete array (see below), it
is foreseen that “targeted arrays” to indicate aneuploidy and
known microdeletion/duplication syndromes may be an
option in the future [15].
Investigation of cancer
Both numerical and structural imbalances occur in (pre-)
malignant cells and more and more of these are being
associated with various prognostic factors. Array CGH has
Table 1 Selected studies using molecular karyotyping, the selection criteria and results
Reference Selection criteria Resolution Positive/total pts Findings
Vissers et al. [28] MR/dysmorphism 1 Mb 5/20 3 del, 1 pat
3,500 BACs 25 2 dup, 1 pat
Shaw-Smith et al. [18] Learning disability/dysmorphism 1 Mb 12/50 7 del, 1 pat
3,431 BACs 24 5 dup, 1 pat, 3 mat
Menten et al. [11] MR/MCA 1 Mb 28/140 23 del, 2 pat, 2 mat
3,431 BACs 20 7 dup, 2 pat, 1 mat
Rosenberg et al. [16] MR/MCA 1 Mb 20/81 14 del, 1 pat, 1 mat
3,431 BACs 25 8 dup, 1 pat, 3 mat
Schoumans et al. [17] MR/dysmorphism 1 Mb 4/41 4 del, de novo
2,600 BACs 10
Friedman et al. [4] MR 100 kb 10/100 8 del
10 2 dup
de Vries et al. [3] MR 100 kb 10/100 7 del, de novo
32,447 BACs 10 3 dup, de novo
Thienpont et al. [22] Heart anomaly/dysmorphism 1 Mb 18/60 6 del
3,431 BACs 30 8 dup
3 del/dup; 1 mosaic
Array CGH was carried out except for Friedman et al. [3], where array-based SNP genotyping was performed. The percentage of positive
imbalances does not represent the percentage pathogenic results
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brought a greater number of these to light and is changing the
nature of their diagnoses. For example, using CGH, consistent
genetic alterations were shown to be associated with primary
cutaneous B-cell lymphomas [10]. However, the investiga-
tion of cancers is outside the scope of this review.
Research applications of array CGH
Gene identification
Traditional chromosome analysis has led to the identifi-
cation of disease genes after one or more cases with a
specific pathology were found to have the same chromo-
some translocation-breakpoint or deletion. Since molecular
karyotyping now enables the rapid detection of small chromo-
somal imbalances, gene identification has dramatically
increased. Dosage-sensitive genes are now detected on
screening numerous patients with a specific pathology and
the detection of a patient with a microdeletion/duplication
locates the region of the genes involved in the pathology.
Using this method, for example, the CHD7 gene responsi-
ble for autosomal dominantly inherited (with many de novo
cases) CHARGE syndrome was identified (reviewed in
[29]). Likewise, the B3GALTL gene was found to be
mutated in patients with the autosomal recessively inherited
Peters Plus syndrome [9]. It is likely that the function of
many more genes will be identified in this way.
Genotype–phenotype correlations
Array CGH is also used at the “full-tiling path” level, where
the selected clones overlap, and so, the exact breakpoints of
the aberrations can be determined. This is used in the
known microdeletion/duplication syndromes which involve
multiple genes. The purpose here is to correlate the various
components of the phenotype with the loci/genes within the
affected chromosomal region. For example, array CGH and
FISH analysis permitted the delineation of the 2q32.2q33
syndrome in four patients, which were then compared to a
further nine patients. All of these cases shared a minimal
deleted chromosomal region and striking phenotypic
similarities. As all patients had a cleft or high palate, it
was speculated that hemizygosity of the SATB2 gene within
this region may be the underlying cause [24].
Challenges in interpretation
Copy number variation/polymorphisms
Numerous regions with non-pathogenic variations in the
number of DNA copies (more or less than two copies) are
scattered throughout the human genome. Using both array
CGH and single nucleotide polymorphism (SNP) genotyp-
ing arrays on the 270 individuals of the HapMap
collection from ancestry in Europe, Africa and Asia,
1,447 sub-microscopic copy variable regions in the human
genome were found [14]. This involves at least 12% of the
genome and includes hundreds of genes in deletions,
duplications, insertions and complex multi-site variants.
Interestingly, population-specific copy number variations
have been detected, which needs to be considered when
analysing the results of patients. This is facilitated by access
to the Database of Genomic Variants (http://projects.tcag.
ca/variation/) and also the results of the HapMap collection
mentioned above [14], both of which are visualised in
Ensembl (http://www.ensembl.org/).
In the clinical/diagnostic setting, the relevance of these
copy number variations is challenging. The finding of an
imbalance does not automatically indicate pathogenicity. At
present, the following reasoning is followed in the analysis
of array CGH results:
– If the imbalance is familial and not a known benign
copy number variation, the phenotypic relationship is
difficult to interpret
– If the aberration in a patient involves a known micro-
deletion/duplication syndrome, the imbalance is con-
sidered as pathogenic
– If the imbalance has occurred de novo in the patient,
and especially if it contains genes with effects
compatible with the clinical findings of the patient,
this is in support of its pathogenicity but is not absolute
proof
In conclusion, the pathogenicity of a chromosomal
imbalance in a patient needs to be proved in order to be
of use in the management of the patient and in counselling
the family as to the implications [2]. To this end, the
collaborative efforts through international databases such as
Decipher and Ecaruca will, hopefully, with time, permit the
detection of similar cases and the determination of the
pathogenicity of the individual aberrations.
Thus, when investigating a patient using molecular
karyotyping, investigation of the parents and additional
family members may often be necessary in order to
interpret the results. Without the availability of DNA from
parents, molecular karyotyping at the higher (100-kb)
resolution is not possible, as the hundreds of polymor-
phisms may be difficult to interpret.
Concluding remarks
The introduction of molecular karyotyping has doubled the
detection rate of chromosomal imbalances in patients with
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mental retardation and multiple congenital anomalies or
dysmorphism and is, therefore, rapidly being introduced as
a routine diagnostic technique in genetic diagnostic centres.
It is, however, important to carefully select patients to
undergo this investigation, as mutations in single-gene
disorders will not be detected. Also, the technology is
advancing the gene detection rate at a faster pace. The
understanding of copy number variations in the human
genome is now better understood than ever and its
implications in diagnosis and the implications in genetic
counselling are being rapidly uncovered. This is challeng-
ing the sector into re-thinking the indications for traditional
chromosome analysis as opposed to molecular karyotyping.
References
1. Ciccone R, Giorda R, Gregato G, Guerrini R, Giglio S, Carrozzo
R, Bonaglia MC, Priolo E, Laganà C, Tenconi R, Rocchi M,
Pramparo T, Zuffardi O, Rossi E (2005) Reciprocal translocations:
a trap for cytogenetists? Hum Genet 117(6):571–582
2. de Ravel TJL, Balikova I, Thienpont B, Hannes F, Maas N, Fryns
J-P, Devriendt K, Vermeesch JR (2006) Molecular karyotyping of
patients with MCA/MR: the blurred boundary between normal and
pathogenic variation. Cytogen Genome Res 115(3–4):225–230
3. de Vries BBA, Pfundt R, Leisink M, Koolen DA, Vissers LELM,
Janssen IM, van Reijmersdal S, Nillesen WM, Huys EHLPG, de
Leeuw N, Smeets D, Sistermans EA, Feuth T, van Ravenswaaij-
Arts CMA, van Kessel AG, Schoenmakers EFPM, Brunner HG,
Veltman JA (2005) Diagnostic genome profiling in mental
retardation. Am J Hum Genet 77(4):606–616
4. Friedman JM, Baross A, Delaney AD, Ally A, Arbour L, Asano J,
Bailey DK, Barber S, Birch P, Brown-John M, Cao M, Chan S,
Charest DL, Farnoud N, Fernandes N, Flibotte S, Go A, Gibson WT,
Holt RA, Jones SJM, Kennedy GC, Krzywinski M, Langlois S, Li
HI, McGillivray BC, Nayar T, Pugh TJ, Rajcan-Separovic E, Schein
JE, Schnerch A, Siddiqui A, Van Allen MI, Wilson G, Yong S-L,
Zahir F, Eydoux P, Marra MA (2006) Oligonucleotide microarray
analysis of genomic imbalance in children with mental retardation.
Am J Hum Genet 79(3):500–513
5. Gribble SM, Prigmore E, Burford DC, Porter KM, Ng BL,
Douglas EJ, Fiegler H, Carr P, Kalaitzopoulos D, Clegg S,
Sandstrom R, Temple IK, Youings SA, Thomas NS, Dennis NR,
Jacobs PA, Crolla JA, Carter NP (2005) The complex nature of
constitutional de novo apparently balanced translocations in
patients presenting with abnormal phenotypes. J Med Genet 42
(1):8–16
6. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW,
Waldman F, Pinkel D (1992) Comparative genomic hybridization
for molecular cytogenetic analysis of solid tumors. Science 258
(5083):818–821
7. Koolen DA, Vissers LELM, Pfundt R, de Leeuw N, Knight SJL,
Regan R, Kooy RF, Reyniers E, Romano C, Fichera M, Schinzel
A, Baumer A, Anderlid B-M, Schoumans J, Knoers NV, van
Kessel AG, Sistermans EA, Veltman JA, Brunner HG, de Vries
BBA (2006) A new chromosome 17q21.31 microdeletion syn-
drome associated with a common inversion polymorphism. Nature
Genet 38(9):999–1001
8. Lejeune J, Gautier M, Turpin R (1959) Études des chromosomes
somatiques de neuf enfants mongoliens. C R Acad Sci 248
(11):1721–1722
9. Lesnik Oberstein SAJ, Kriek M, White SJ, Kalf ME, Szuhai K,
den Dunnen JT, Breuning MH, Hennekam RCM (2006) Peters
Plus syndrome is caused by mutations in B3GALTL, a putative
glycosyltransferase. Am J Hum Genet 79(3):562–566
10. Mao X, Lillington D, Child F, Russell-Jones R, Young B,
Whittaker S (2002) Comparative genomic hybridization analysis
of primary cutaneous B-cell lymphomas: identification of com-
mon genomic alterations in disease pathogenesis. Genes Chromo-
somes Cancer 35(2):144–155
11. Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J,
Melotte C, de Ravel T, Van Vooren S, Balikova I, Backx L,
Janssens S, De Paepe A, De Moor B, Moreau Y, Marynen P,
Fryns J-P, Mortier G, Devriendt K, Speleman F, Vermeesch JR
(2006) Emerging patterns of cryptic chromosomal imbalances in
patients with idiopathic mental retardation and multiple congenital
anomalies: a new series of 140 patients and review of the
literature. J Med Genet 43:625–633
12. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D,
Collins C, Kuo W-L, Chen C, Zhai Y, Dairkee SH, Ljung B-M,
Gray JW, Albertson DG (1998) High resolution analysis of DNA
copy number variation using comparative genomic hybridization
to microarrays. Nature Genet 20(2):207–211
13. Redon R, Baujat G, Sanlaville D, Le Merrer M, Vekemans M,
Munnich A, Carter NP, Cormier-Daire V, Colleaux L (2006)
Interstitial 9q22.3 microdeletion: clinical and molecular character-
isation of a newly recognised overgrowth syndrome. Eur J Hum
Genet 14(6):759–767
14. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD,
Fiegler H, Shapero MH, Carson AR, Chen W, Kyung Cho E,
Dallaire S, Freeman JL, González JR, Gratacòs M, Huang J,
Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R,
Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ,
Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T,
Zhang J, Armengol L, Conrad DF, Estivill X, Tyler-Smith C,
Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME
(2006) Global variation in copy number in the human genome. Nature
444(7118):444–454
15. Rickman L, Fiegler H, Shaw-Smith C, Nash R, Cirigliano V,
Voglino G, Ng BL, Scott C, Whittaker J, Adinolfi M, Carter NP,
Bobrow M (2006) Prenatal detection of unbalanced chromosomal
rearrangements by array CGH. J Med Genet 43(4):353–361
16. Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM,
Sloos W, Otto PA, Kriek M, Hansson K, Krepischi-Santos ACV,
Fiegler H, Carter NP, Bijlsma EK, van Haeringen A, Szuhai K,
Tanke HJ (2006) Array-CGH detection of micro rearrangements
in mentally retarded individuals: clinical significance of imbal-
ances present both in affected children and normal parents. J Med
Genet 43(2):180–186
17. Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M,
Anderlid B-M, Nordenskjöld M (2005) Detection of chromosomal
imbalances in children with idiopathic mental retardation by array
based comparative genomic hybridisation (array-CGH). J Med
Genet 42(9):699–705
18. Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, Fiegler H,
Firth H, Sanlaville D, Winter R, Colleaux L, Bobrow M, Carter NP
(2004) Microarray based comparative genomic hybridisation (array-
CGH) detects submicroscopic chromosomal deletions and duplica-
tions in patients with learning disability/mental retardation and
dysmorphic features. J Med Genet 41(4):241–248
19. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L,
Gribble S, Curley R, Cumming S, Dunn C, Kalaitzopoulos D, Porter
K, Prigmore E, Krepischi-Santos AC, Varela MC, Koiffmann CP,
Lees AJ, Rosenberg C, Firth HV, de Silva R, Carter NP (2006)
Microdeletion encompassing MAPT at chromosome 17q21.3 is
associated with developmental delay and learning disability. Nature
Genet 38(9):1032–1037
642 Eur J Pediatr (2007) 166:637–643
20. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A,
Döhner H, Cremer T, Lichter P (1997) Matrix-based comparative
genomic hybridization: biochips to screen for genomic imbalances.
Genes Chromosomes Cancer 20(4):399–407
21. Speicher MR, Ballard SG, Ward DC (1996) Karyotyping human
chromosomes by combinatorial multi-fluor FISH. Nature Genet
12(4):368–375
22. Thienpont B,Mertens L, de Ravel T, Eyskens B, Boshoff D,Maas N,
Fryns J-P, Gewillig M, Vermeesch JR, Devriendt K (2007)
Submicroscopic chromosomal imbalances detected by array-CGH
are a frequent cause of congenital heart defects in selected patients.
Eur Heart J (in press)
23. Tjio JH, Levan A (1956) The chromosome number of man.
Hereditas 42:1–6
24. Van Buggenhout G, Van Ravenswaaij-Arts C, Mc Maas N,
Thoelen R, Vogels A, Smeets D, Salden I, Matthijs G, Fryns
J-P, Vermeesch JR (2005) The del(2)(q32.2q33) deletion syn-
drome defined by clinical and molecular characterization of four
patients. Eur J Med Genet 48(3):276–289
25. Veltman JA (2006) Genomic microarrays in clinical diagnosis.
Curr Opin Pediatr 18(6):598–603
26. Vermeesch JR, Melotte C, Froyen G, Van Vooren S, Dutta B,
Maas N, Vermeulen S, Menten B, Speleman F, De Moor B, Van
Hummelen P, Marynen P, Fryns J-P, Devriendt K (2005)
Molecular karyotyping: array CGH quality criteria for constitu-
tional genetic diagnosis. J Histochem Cytochem 53(3):413–422
27. Vermeesch JR, Rauch A (2006) Reply to Hochstenbach et al. 2006
‘Molecular karyotyping’. Eur J Hum Genet 14(10):1063–1064
28. Vissers LELM, de Vries BBA, Osoegawa K, Janssen IM, Feuth T,
Choy CO, Straatman H, van der Vliet W, Huys EHLPG, van Rijk A,
Smeets D, van Ravenswaaij-Arts CMA, Knoers NV, van der Burgt I,
de Jong PJ, Brunner HG, van Kessel AG, Schoenmakers EFPM,
Veltman JA (2003) Array-based comparative genomic hybridization
for the genomewide detection of submicroscopic chromosomal
abnormalities. Am J Hum Genet 73(6):1261–1270
29. Vissers LELM, Veltman JA, van Kessel AG, Brunner HG (2005)
Identification of disease genes by whole genome CGH arrays.
Hum Molec Genet 14(2):R215–R223
Eur J Pediatr (2007) 166:637–643 643
